"It's about painting a picture of the future and finding the best way to bring people with you on that journey."

Simon Marriott, Senior R&D Business Analyst, MedImmune

As the global biologics research and development arm of AstraZeneca, MedImmune is a pioneering force with a robust and innovative pipeline of more than 120 clinical and preclinical programmes. MedImmune is credited as having developed the first and only live intranasal quadrivalent flu vaccine, the first and only FDA-approved medication to help protect high-risk babies’ lungs from severe respiratory syncytial virus (RSV) disease, and the first FDA approved monoclonal antibody for an infectious disease.

In 2014, MedImmune challenged the norms of how an ELN should be implemented. Within an eightmonth
timeframe, deployment took place across three sites in their entirety, from early discovery to clinical manufacturing, and included all of R&D.

This article highlights how the ELN project team effectively challenged the status quo of how an ELN is selected, deployed and implemented.

Please complete this form to request this BIOVIA Customer Story »

MedImmune - Innovation through Implementation

BIOVIA Customer Story

BIOVIA Customer Story Access
Complete this form to receive your content